Deep Value: cash covers more than 100% of the stock price

This company holds roughly $17M in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Kiora Pharmaceuticals

KPRX

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Kiora Pharmaceuticals is a small biotech company focused on developing drugs to treat eye diseases. Its pipeline targets conditions like wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other retinal disorders that can cause vision loss. The company's main customers would be patients and eye care specialists, and it operates in the competitive ophthalmology drug development space.

Kiora does not yet sell approved products, so it currently generates no meaningful revenue — it funds operations through equity raises and grants while spending on clinical trials. The company is based in the United States and, with a market cap near zero, is considered a micro-cap or nano-cap firm. Its main competitive challenge is proving its drug candidates work better or more conveniently than existing treatments, and the biggest risk is that clinical trials fail or funding runs out before any product reaches the market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-11.5% YoY

YoY Growth Rate

Earnings declining

Insider Activity

5.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~13 months

$14M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-17.7%

Weak — -17.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.01

Conservative — low debt load (0.01)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial